Casearin D inhibits ERK phosphorylation and induces downregulation of cyclin D1 in HepG2 cells. (February 2017)

• Record Type: Journal Article
• Authors: Ferreira-Silva, Guilherme Álvaro; Lages, Carla Carolina Lopes; Sartorelli, Patricia; Hasegawa, Flávia Rie; Soares, Marisi Gomes; Ionta, Marisa
• Is Part Of: Toxicology in vitro. Volume 38(2017)
• Page Start: 27
• Page End: 32
• Publication Date: 2017-02
• Subjects: Hepatocellular carcinoma -- Cell cycle arrest -- Cyclin D1 expression -- Casearins -- Casearia sylvestris; Toxicity testing -- In vitro -- Periodicals; Toxicology -- Periodicals; 615.9
• DOI: 10.1016/j.tiv.2016.10.011
• Languages: English
• ISSNs: 0887-2333

Abstract

Abstract: Cancer is a public health problem which represents the second cause of death in the world. In this framework, it is necessary to identify novel compounds with antineoplastic potential. Plants are an important source for discovering novel compounds with pharmacological potential. In this study, we aimed to investigate the antiproliferative potential of isolated compounds from Casearia sylvestris on tumor cell lines. Crude extract effectively reduced cell viability of 4 tumor cell lines (HepG2, A549, U251-MG, and HT-144) after 48 h treatment. HepG2 and HT-144 were the most responsive cells. Three fractions (aqueous ethanol, n -hexane and ethyl acetate) were tested against HepG2 and HT-144 cells and we observed that compounds with antiproliferative activity were concentrated in n -hexane and ethyl acetate fractions. The casearins A, G and J were isolated from n -hexane fraction, while casearin D was obtained from ethyl acetate fraction. We demonstrated that casearin D significantly inhibited the clonogenic capacity of HepG2 cells after 24 h exposure indicating its antiproliferative activity. In addition, G1/S transition cell cycle arrest in HepG2 cells was also observed. These effects are related, at least in part, to ability of the casearin D in reducing ERK phosphorylation and cyclin D1 expression levels. Highlights: Casearin D inhibits cell cycle progression of HepG2 cells. Casearin D treatment reduces ERK phosphorylation levels in HepG2 cells. Cyclin D1 expression is reduced in HepG2 cells after treatment with Casearin D.